Sugi Predict

Sugi Predict / Compounds / SCHEMBL4037235

SCHEMBL4037235

SCHEMBL4037235

O=S(=O)(c1ccccc1)N1CC[CH]CC1

nearest known ligand 0.63

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 2/20 0.63
▸ PKM P14618 2/20 0.61
▸ ALDH1A1 P00352 3/20 0.59
▸ LMNA P02545 1/20 0.59
▸ CYP2C9 P11712 1/20 0.57
▸ GAA P10253 3/20 0.56
▸ MEN1 O00255 2/20 0.56
▸ KMT2A Q03164 2/20 0.56
▸ CYP2D6 P10635 1/20 0.56
▸ MAPK1 P28482 1/20 0.56
▸ L3MBTL1 Q9Y468 1/20 0.56
▸ APOBEC3A P31941 1/20 0.54
▸ APOBEC3G Q9HC16 1/20 0.54
▸ TSHR P16473 1/20 0.54
▸ SMN1; SMN2 Q16637 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17911166 0.88 ALDH1A1 (0.56) POLBPKMALDH1A1LMNACYP2C9
SCHEMBL735657 0.87 POLB (0.80) POLBPKMALDH1A1LMNACYP2C9
SCHEMBL7122592 0.87 POLB (0.80) POLBPKMALDH1A1LMNACYP2C9
SCHEMBL3830424 0.87 POLB (0.80) POLBPKMALDH1A1LMNACYP2C9
SCHEMBL14470279 0.83 ALDH1A1 (0.75) POLBPKMALDH1A1LMNACYP2C9
SCHEMBL6805741 0.83 ALDH1A1 (0.81) POLBPKMALDH1A1LMNACYP2C9
SCHEMBL1988224 0.83 ALDH1A1 (0.81) POLBPKMALDH1A1LMNACYP2C9
SCHEMBL10445162 0.81 ALDH1A1 (0.85) POLBPKMALDH1A1LMNACYP2C9
SCHEMBL1902263 0.81 ALDH1A1 (0.85) POLBPKMALDH1A1LMNACYP2C9
SCHEMBL295028 0.80 PKM (0.70) POLBPKMALDH1A1LMNAGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10407430-B2 Janus kinase 1 selective inhibitor and pharmaceutical use thereof YANG JI CHEMICAL CO., LTD. (KR) 2019-09-10 — — US claimed
US-20180237440-A1 JANUS KINASE 1 SELECTIVE INHIBITOR AND PHARMACEUTICAL USE THEREOF YANG JI CHEMICAL CO., LTD. (KR) 2018-08-23 — — US claimed
CN-108137608-A Janus kinase 1 selective inhibitor and pharmaceutical application thereof 阳智化学（株） 2018-06-08 — — CN claimed
EP-3327021-A1 JANUS KINASE 1 SELECTIVE INHIBITOR AND PHARMACEUTICAL USE THEREOF Yangji Chemical Co., Ltd. (KR) 2018-05-30 — — EP claimed
US-9732061-B2 Cinnoline derivatives useful as CB-1 receptor inverse agonists JANSSEN PHARMACEUTICA NV (BE) 2017-08-15 — — US claimed
WO-2016115013-A1 CINNOLINE DERIVATIVES USEFUL AS CB-1 RECEPTOR INVERSE AGONISTS JANSSEN PHARMACEUTICA NV (BE) 2016-07-21 — — WO claimed
US-20160200719-A1 CINNOLINE DERIVATIVES USEFUL AS CB-1 RECEPTOR INVERSE AGONISTS JANSSEN PHARMACEUTICA NV (BE) 2016-07-14 — — US claimed
EP-1537123-B1 AMINO-SUBSTITUTED CYCLOHEXANE DERIVATIVES FOR THE TREATMENT OF BACTERIAL INFECTIONS GLAXO GROUP LTD (GB) 2009-04-29 — — EP claimed
EP-1546150-B1 PYRROLE DERIVATIVES AS INHIBITORS OF CYTEINE PROTEASES AMURA THERAPEUTICS LTD (GB) 2009-03-04 — — EP claimed
EP-1436291-B1 INDOLIZINES AS KINASE PROTEIN INHIBITORS AVENTIS PHARMA SA (FR) 2009-01-14 — — EP claimed
US-20060100431-A1 Biologically active compounds AMURA THERAPEUTICS LIMITED (GB) 2006-05-11 — — US claimed
US-7034043-B2 Cell adhesion inhibitors BIOGEN IDEC MA INC. (US) 2006-04-25 — — US claimed
CN-1207056-C Peptide-containing alpha-ketoamide cysteine and serine protease inhibitors CEPHALEN INC (US) 2005-06-22 — — CN claimed
EP-1436291-A2 INDOLIZINES AS KINASE PROTEIN INHIBITORS Aventis Pharma S.A. (FR) 2004-07-14 — — EP claimed
US-20040132809-A1 Cell adhesion inhibitors BIOGEN, INC. 2004-07-08 — — US claimed
WO-2003024967-A2 INDOLIZINES AS KINASE PROTEIN INHIBITORS AVENTIS PHARMA S.A. (FR) 2003-03-27 — — WO claimed
EP-3989997-A1 COMPOUNDS AND METHODS FOR TREATING CANCER, VIRAL INFECTIONS, AND ALLERGIC CONDITIONS Washington University (US) 2022-05-04 — — EP disclosed
WO-2020264187-A1 COMPOUNDS AND METHODS FOR TREATING CANCER, VIRAL INFECTIONS, AND ALLERGIC CONDITIONS JANETKA JAMES (US) 2020-12-30 — — WO disclosed
CN-1274288-A Peptide-containing & alpha, -ketoamide cysteine and serine protease inhibitors CEPHALEN INC (US) 2000-11-22 — — CN disclosed
US-6150378-A 1-((1-HALO-SUBSTITUTEDBENZOYLAMINO)-2-PHENYLETHYL)-CARBONYL -CARBONYLAMINO),2-PHENYL OR PYRID-2-YLSULFAMIDO)ETHANE DERIVATIVES; MUSCULAR DYSTROPHY, NEURODEGENERATION, STROKE, ALZHEIMER'S, AMYOTROPHY, MOTOR NEURON DAMAGE, CNS INJURY CEPHALON, INC. (US) 2000-11-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10407430-B2 Janus kinase 1 selective inhibitor and pharmaceutical use thereof JAK1, JAK2, JAK3 POLB 3589/4885PKM 433/4885ALDH1A1 937/4885
US-20040132809-A1 Cell adhesion inhibitors VCAM1, ICAM1, EPCAM POLB 4538/4885PKM 4673/4885ALDH1A1 631/4885
US-20180237440-A1 JANUS KINASE 1 SELECTIVE INHIBITOR AND PHARMACEUTICAL USE THEREOF JAK1, JAK2, JAK3 POLB 3798/4885PKM 746/4885ALDH1A1 1938/4885
US-20060100431-A1 Biologically active compounds SOST, CTSK, CTSS POLB 3780/4885PKM 2918/4885ALDH1A1 4151/4885
US-20160200719-A1 CINNOLINE DERIVATIVES USEFUL AS CB-1 RECEPTOR INVERSE AGONISTS CNR1, CNR2, GPR119 POLB 3939/4885PKM 3784/4885ALDH1A1 828/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.